|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 408.00 USD | +6.04% |
|
-.--% | -6.49% |
| 07-14 | Where would AI lead Pharma in the long run? | ![]() |
| 06-19 | IBM Renews Its Partnership With France's Virbac |
Company Valuation: Virbac
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,584 | 1,927 | 3,035 | 2,651 | 2,995 | 2,681 | - | - |
| Change | - | -46.24% | 57.52% | -12.67% | 13% | -10.49% | - | - |
| Enterprise Value (EV) 1 | 3,510 | 1,848 | 2,983 | 2,819 | 3,168 | 2,802 | 2,707 | 2,560 |
| Change | - | -47.37% | 61.45% | -5.49% | 12.37% | -11.55% | -3.37% | -5.45% |
| P/E | 31.7x | 15.8x | 25x | 18.3x | 19.9x | 15.8x | 14.2x | 12.8x |
| PBR | 4.95x | 2.29x | 3.34x | 2.54x | 2.66x | 2.11x | 1.86x | 1.65x |
| PEG | - | 2.06x | -72.15x | 0.9x | 5.23x | 1.3x | 1.3x | 1.2x |
| Capitalization / Revenue | 3.37x | 1.58x | 2.43x | 1.9x | 2.04x | 1.73x | 1.63x | 1.55x |
| EV / Revenue | 3.3x | 1.52x | 2.39x | 2.02x | 2.16x | 1.81x | 1.65x | 1.48x |
| EV / EBITDA | 16.3x | 8.27x | 12.8x | 9.96x | 10.9x | 8.97x | 7.84x | 6.76x |
| EV / EBIT | 20.8x | 10.1x | 16.1x | 12.4x | 13.8x | 11.1x | 9.75x | 8.38x |
| EV / FCF | 36.5x | 40.7x | 50.8x | 22.8x | 29.7x | 33.3x | 22.7x | 15.7x |
| FCF Yield | 2.74% | 2.46% | 1.97% | 4.39% | 3.37% | 3.01% | 4.41% | 6.37% |
| Dividend per Share 2 | 1.25 | 1.32 | 1.32 | 1.45 | 1.45 | 1.721 | 2.04 | 2.566 |
| Rate of return | 0.29% | 0.58% | 0.37% | 0.46% | 0.41% | 0.54% | 0.64% | 0.8% |
| EPS 2 | 13.4 | 14.43 | 14.38 | 17.34 | 18 | 20.24 | 22.54 | 24.91 |
| Distribution rate | 9.33% | 9.15% | 9.18% | 8.36% | 8.06% | 8.5% | 9.05% | 10.3% |
| Net sales 1 | 1,064 | 1,216 | 1,247 | 1,397 | 1,465 | 1,548 | 1,645 | 1,730 |
| EBITDA 1 | 215.1 | 223.4 | 232.8 | 283 | 289.5 | 312.2 | 345.3 | 378.7 |
| EBIT 1 | 168.9 | 182.8 | 184.9 | 227.5 | 229.7 | 252.7 | 277.7 | 305.3 |
| Net income 1 | 113.2 | 122 | 121.3 | 145.3 | 150.9 | 168.5 | 189.5 | 210.4 |
| Net Debt 1 | -73.83 | -79.36 | -52.36 | 168.5 | 172.8 | 121 | 26.49 | -120.9 |
| Reference price 2 | 424.50 | 228.00 | 359.50 | 316.50 | 357.50 | 320.00 | 320.00 | 320.00 |
| Nbr of stocks (in thousands) | 8,443 | 8,451 | 8,443 | 8,375 | 8,378 | 8,378 | - | - |
| Announcement Date | 3/22/22 A | 3/23/23 A | 3/19/24 A | 3/13/25 A | 3/17/26 A | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 11.59x | 3.87x | 8.85x | 2.91% | 31.25B | ||
| 260.71x | 3.11x | 15.7x | -.--% | 12.76B | ||
| 7.33x | 1.05x | 3.88x | 3.58% | 3.59B | ||
| 50.38x | - | - | 0.71% | 1.97B | ||
| 29.48x | 3.54x | 12.71x | -.--% | 1.73B | ||
| 13.35x | 1.26x | 7.49x | 1.45% | 1.37B | ||
| 16.42x | 2.07x | 9.55x | 1.87% | 1.09B | ||
| 15.18x | 1.08x | 5.13x | 1.29% | 965M | ||
| 31.25x | - | - | 0.48% | 983M | ||
| Average | 48.41x | 2.28x | 9.05x | 1.37% | 6.19B | |
| Weighted average by Cap. | 70.84x | 3.33x | 10.21x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- VIRP Stock
- VRBCF Stock
- Valuation Virbac
Select your edition
All financial news and data tailored to specific country editions

















